ANALYSIS: Teva takes it step by step in Brazil
This article was originally published in Scrip
While Teva is known as a generics giant in most markets, in Brazil things are different. Here the firm is more active as an innovator, although not for want of trying to make its mark in the Brazilian generics space. The firm talked to Scrip about its step by step approach and why this challenging market is still worth the trouble.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.